Key Takeaways
- Iran launched ballistic missiles and drones at U.S. military bases in Jordan and the UAE early Monday, marking a major escalation in the six-month conflict.
- OpenAI received warrants valued at $5.5 billion in SB Energy, a SoftBank-backed firm, as the AI giant moves to secure massive power infrastructure for its data centers.
- Global gas asset dealmaking hit a 10-year high, with over $32 billion spent in the first half of 2026 as energy security concerns intensify.
- Romania is set to lose €770 million in EU recovery funds after a domestic political crisis prevented the government from meeting a critical August 31 reform deadline.
- Jefferies raised its price target for Protagonist Therapeutics (PTGX) to $171, reflecting bullish sentiment following recent drug approvals and commercial transitions.
Geopolitical Tensions Reach Boiling Point
The Middle East conflict has entered a dangerous new phase as Iran’s Foreign Ministry confirmed its forces targeted U.S. military bases in Jordan and the Al Minhad Air Base in the UAE. The strikes, involving both ballistic missiles and drones, were described by Tehran as direct retaliation for a U.S. attack on Larak Island on Sunday. Iranian state media reported that the Larak Island strike resulted in several casualties, including military personnel and civilians, for which Iran holds the U.S. and its backers "fully responsible."
Jordanian authorities reported intercepting at least eight missiles that entered their airspace, while the UAE has elevated its security threat level for residents in Dubai. The escalation has immediately impacted global energy sentiment, as the Strait of Hormuz remains a central chokepoint for oil and gas transit. U.S. Central Command (CENTCOM) previously stated the Larak Island strike was a "limited, precise action" intended to stop the deployment of sea mines.
OpenAI’s $5.5 Billion Power Play
In a landmark deal for the AI sector, OpenAI has reportedly acquired warrants valued at $5.5 billion in SB Energy, a power infrastructure company controlled by SoftBank Group (SFTBY). According to the Wall Street Journal, the warrants were part of a massive incentive package to secure OpenAI as a long-term tenant for high-capacity data centers. The deal underscores the "gigawatt-scale" energy requirements needed to sustain the next generation of artificial intelligence models.
This partnership ties into a broader infrastructure web involving Nvidia (NVDA), which has also invested $1.5 billion in SB Energy. The companies are collaborating on massive projects, including a 1.2-gigawatt data center in Texas and an 8-gigawatt IT park in Ohio. Analysts suggest this vertically integrated approach to power and compute is becoming the new standard for AI leaders seeking to bypass grid bottlenecks.
Energy Markets and Macroeconomic Shifts
The scramble for energy security has pushed natural gas dealmaking to its highest level in more than a decade. The Financial Times reports that $32 billion was spent on gas production assets in the first half of 2026, a frenzy fueled by the ongoing war in the Middle East and rising demand from data centers. Major energy players like Shell (SHEL) have led the charge, with Shell’s $16.4 billion acquisition of ARC Resources marking its largest deal in ten years.
In Europe, Romania is facing a significant financial blow, forfeiting €770 million in EU pandemic recovery funds. The loss stems from a political deadlock that prevented the adoption of public-sector wage reforms by the August 31 deadline. The failure to secure these grants adds immediate pressure to Romania’s national budget and credit rating, which were already strained by a widening deficit.
Healthcare and Biotech Updates
On the financial front, Jefferies has increased its price target for Protagonist Therapeutics (PTGX) to $171, up from $169. The revision follows the company's successful transition to a commercial-stage entity after the FDA approval of its psoriasis treatment, Icotyde. The stock has seen a significant rally in 2026, supported by beating Q2 earnings estimates and a strong cash position of nearly $850 million. Investors are now looking toward upcoming regulatory decisions for rusfertide, which could further solidify the company's position in the immunology market.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.